Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.44 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | PLK1 | P53350 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28281865 | 0.88 | PLA2G2A (0.47) | KMT2ACYP1A2CYP2C19CYP3A4PKM | |
| SCHEMBL12687133 | 0.88 | MAOA (0.52) | KDM4ECYP1A2CYP2C19HPGDTTBK1 | |
| SCHEMBL31459933 | 0.87 | KDM4E (0.54) | KDM4ETDP1KMT2ACYP1A2CYP2C19 | |
| SCHEMBL31225318 | 0.87 | KDM4E (0.50) | KDM4ETDP1KMT2ACYP1A2PKM | |
| SCHEMBL20429979 | 0.86 | KMT2A (0.45) | KDM4ETDP1KMT2ACYP1A2CYP2C19 | |
| SCHEMBL21543853 | 0.85 | TDP1 (0.55) | KDM4ETDP1KMT2ACYP1A2CYP2C19 | |
| SCHEMBL13213369 | 0.84 | CYP1A2 (0.48) | KDM4EKMT2ACYP1A2CYP2C19CYP3A4 | |
| SCHEMBL3988817 | 0.83 | KDM4E (0.57) | KDM4ETDP1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL4649128 | 0.83 | TSHR (0.60) | KDM4EKMT2ACYP1A2PKMHPGD | |
| SCHEMBL9197444 | 0.83 | XDH (0.53) | KDM4EKMT2ACYP1A2CYP2C19CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066359-A1 | SOMATOSTATIN RECEPTOR SUBTYPE 5 ANTAGONISTS, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2025-02-27 | — | — | US | disclosed |
| WO-2023125486-A1 | SOMATOSTATIN RECEPTOR SUBTYPE 5 ANTAGONISTS, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 中国科学院上海药物研究所 | 2023-07-06 | — | — | WO | disclosed |
| CN-116354961-A | Somatostatin receptor 5 antagonist, and pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2023-06-30 | — | — | CN | disclosed |
| CN-109970797-A | Hydroxyformamide derivatives and application thereof | 葛兰素史密斯克莱知识产权（第2 号）有限公司 | 2019-07-05 | — | — | CN | disclosed |
| CN-106103431-B | Hydroxycarboxamide derivatives and their use | 葛兰素史密斯克莱知识产权（第2 号）有限公司 | 2019-03-15 | — | — | CN | disclosed |
| CN-105555766-A | Aminomethyl-biaryl derivatives as complement factor D inhibitors and uses thereof | NOVARTIS AG | 2016-05-04 | — | — | CN | disclosed |
| EP-1701933-B1 | NOVEL COMPOUNDS | MITSUBISHI TANABE PHARMA CORP (JP) | 2008-09-03 | — | — | EP | disclosed |
| US-20070043113-A1 | Novel compounds | TANABE SEIYAKU CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| CN-1898197-A | Novel compound | TANABE SEIYAKU CO (JP) | 2007-01-17 | — | — | CN | disclosed |
| EP-1701933-A1 | NOVEL COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 2006-09-20 | — | — | EP | disclosed |
| WO-2005061440-A1 | NOVEL COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043113-A1 | Novel compounds | VCAM1, ICAM1, EPCAM | KDM4E 2476/4885TDP1 1099/4885KMT2A 3401/4885 |
| US-20250066359-A1 | SOMATOSTATIN RECEPTOR SUBTYPE 5 ANTAGONISTS, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | SSTR5, SSTR2, SSTR3 | KDM4E 4363/4885TDP1 3987/4885KMT2A 4696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.